Active Research Protocols
- 10-I-0101 – A Randomized, Placebo-controlled, Double-Blind Pilot Study of Single-Dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa Loa Infection
- 88-I-0083 – Host Response to Infection and Treatment in the Filarial Diseases of Humans
NOTE: PDF documents require the freeAdobe Reader.
This page was last updated: January 24, 2014